首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1716265

G蛋白偶聯受體（GPCR）標靶化：技術與全球市場

G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets

出版日期: 2025年04月23日 | 出版商:

BCC Research | 英文 107 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球 G 蛋白偶聯受體 (GPCR)標靶化市場規模預計將從 2024 年的 44 億美元成長到 2029 年底的 61 億美元，預測期內的複合年成長率為 6.8%。

預計北美市場將從 2024 年的 18 億美元成長到 2029 年底的 23 億美元，預測期內的複合年成長率為 5.8%。預計歐洲市場將從 2024 年的 12 億美元成長到 2029 年底的 18 億美元，預測期內的複合年成長率為 7.1%。

本報告涵蓋全球 G 蛋白偶聯受體 (GPCR)標靶化市場，並提供市場概述、市場影響因素和市場機會分析、法律制度、新興技術和技術發展趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場概覽
細分市場
GPCR標靶化：技術與全球市場
按檢測類型進行的市場分析
cAMP 和 cGMP 檢測
鈣功能測定
Arrestin功能測定
放射性配體結合和 GTPγS 功能分析
報導基因分析
其他
按產品類型進行市場分析
細胞株
檢測試劑套件
細胞培養試劑
配體
市場分析：按應用
腫瘤/癌症
心血管疾病
中樞神經系統疾病
呼吸系統疾病
其他
地理分佈
市場分析：按地區
北美洲
歐洲
亞太地區
其他地區

第6章競爭訊息

概述
產業公司排名
產業創業融資

第7章 GPCR 目標科技產業的永續性：ESG 視角

全球GPCR產業的永續性
ESG風險與評級等：解讀數據
BCC 的觀點

第 8 章附錄

來源
簡稱
公司簡介
AGILENT TECHNOLOGIES INC.
BD
DANAHER CORP.
ENZO BIOCHEM INC.
EPICS THERAPEUTICS
EUROFINS SCIENTIFIC
INTERAX BIOTECH AG
MERCK KGAA
ORION BIOTECHNOLOGY CANADA LTD.
PROMEGA CORP.
QIAGEN
REVVITY
TECTONIC THERAPEUTIC
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC

簡介目錄圖表

Product Code: BIO136B

The global G protein-coupled receptor (GPCR) market is expected to grow from $4.4 billion in 2024 and is projected to reach $6.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.

The North American GPCR market is expected to grow from $1.8 billion in 2024 and is projected to reach $2.3 billion by the end of 2029, at a CAGR of 5.8% during the forecast period of 2024 to 2029.

The European GPCR market is expected to grow from $1.2 billion in 2024 and is projected to reach $1.8 billion by the end of 2029, at a CAGR of 7.1% during the forecast period of 2024 to 2029.

Report Scope:

This report on the global market for G protein-coupled receptor (GPCR) targeting technologies analyzes the current landscape, including market size and growth trends and segments the market by assay type, product type, application and region. Assay categories include cAMP assays and cGMP assays, calcium functional assays, arrestin functional assays, radioligand binding and GTPgammaS functional assays, reporter gene assays and others. Product types include cell lines, detection kits, cell culture reagents and ligands. Applications include oncology, cardiovascular diseases (CVDs), central nervous system diseases, respiratory diseases and others.

The regions looked at are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore and Rest of APAC) and the Rest of the World (South America, the Middle East and Africa). The report also includes profiles of leading companies and discusses industry trends, significant products, mergers and acquisitions, and other collaborations or partnerships.

In-text citations are given by the author and the year that the research or study was published. More details on these sources can be found in the table listing them in the Appendix.

Report Includes:

22 data tables and 43 additional tables
An analysis of the global market and technologies for G-protein coupled receptor (GPCR) targeting
Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
Evaluation of the market potential for GPCR targeting technology, industry growth drivers, and forecasts for this market's segments and sub-segments
Estimates of the market size and revenue forecast for the global GPCR targeting technology market in USD millions, and a corresponding market share analysis by assay type, product type, application and region
Discussion of the major market dynamics and shifts, and the regulations, industry challenges and macroeconomic factors affecting the demand for GPCR targeting technology over the coming years
A look at the recent technological breakthroughs in the use of GPCR targeting technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
Review of the patent filings and research publications for innovations in GPCR targeting technology
Discussion on the industry's ESG challenges and practices
Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances or other advantages
Insights into the industry structure for GPCR targeting technology, the competitive landscape, clinical trials and ongoing research activity
Profiles of the major players in the industry, including Promega Corp., Revvity Inc., Thermo Fisher Scientific Inc., Enzo Biochem Inc., and Danaher Corp.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Types of GPCRs
Introduction of GPCR Cellular Responses
Importance of GPCRs in Disease Physiology
Regulatory Aspect

Chapter 3 Market Dynamics

Overview
Market Drivers
Rising Incidence of Chronic Diseases
Growing Demand for GPCR Drugs
Technological Advances in GPCR Research
Market Restraints
Challenges of Drug Discovery
Limitations of GPCR Structural Studies
Market Opportunities
Personalized Cancer Therapy

Chapter 4 Emerging Technologies and Developments

Overview
Emerging Technologies
Novel Screening Technology
Structural Analysis in GPCR-Targeted Drug Discovery
Experimental Screening in GPCR-Targeted Drug Discovery
Patent Analysis
Patent Review, by Applicant

Chapter 5 Market Segmentation Analysis

Market Overview
Segmentation Breakdown
GPCR-Targeting: Technologies and Global Markets
Market Analysis by Assay Type
cAMP Assays and cGMP Assays
Calcium Functional Assays
Arrestin Functional Assays
Radioligand-Binding and GTPgammaS Functional Assays
Reporter Gene Assays
Other Assays
Market Analysis by Product Type
Cell Lines
Detection Kits
Cell Culture Reagents
Ligands
Market Analysis by Application
Oncology/Cancers
Cardiovascular Diseases
Central Nervous System Diseases
Respiratory Diseases
Other Diseases
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Overview
Ranking of Companies in the Industry
Venture Fundings in the Industry

Chapter 7 Sustainability in the GPCR-Targeting Technologies Industry: An ESG Perspective

Sustainability in the Global GPCR Industry
ESG Risks and Ratings: Understanding the Data
BCC Research Viewpoint

Chapter 8 Appendix

Sources
Abbreviations
Company Profiles
AGILENT TECHNOLOGIES INC.
BD
DANAHER CORP.
ENZO BIOCHEM INC.
EPICS THERAPEUTICS
EUROFINS SCIENTIFIC
INTERAX BIOTECH AG
MERCK KGAA
ORION BIOTECHNOLOGY CANADA LTD.
PROMEGA CORP.
QIAGEN
REVVITY
TECTONIC THERAPEUTIC
THERMO FISHER SCIENTIFIC INC.
WUXI APPTEC

簡介目錄圖表

List of Tables

Summary Table : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
Table 1 : Number of New Cases and Deaths Due to Various Cancers, Globally, 2022
Table 2 : U.S. NIH Funding for Various Diseases and Conditions, 2019-2023
Table 3 : FDA-Approved Drugs Targeting GPCR, 2020-2024
Table 4 : Patents Issued for GPCRs, by Applicant, January 2023-December 2024
Table 5 : Global Market for GPCR-Targeting Technologies, Through 2029
Table 6 : Global Market for GPCR Targeting Technologies, by Assay Type, Through 2029
Table 7 : Global Market for GPCR-Targeting Technologies, by Product Type, Through 2029
Table 8 : Global Market for GPCR-Targeting Technologies, by Application, Through 2029
Table 9 : GPCRs, Ligands and Their Locations in the Body
Table 10 : GPCR Families and Their Role in CNS Disorders
Table 11 : Glucocorticoid Effects Mediated by Transactivation Mechanisms in Airway Structural Cells
Table 12 : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
Table 13 : North American Market for GPCR-Targeting Technologies, by Country, Through 2029
Table 14 : European Market for GPCR-Targeting Technologies, by Country, Through 2029
Table 15 : APAC Market for GPCR-Targeting Technologies, by Country, Through 2029
Table 16 : ROW Market for GPCR-Targeting Technologies, by Subregion, Through 2029
Table 17 : Market Rankings of Leading Companies in the GPCR-Targeting Technologies Industry, 2023
Table 18 : Funding for GPCR-Targeting Technologies Companies, 2022-2024
Table 19 : ESG Rankings for Major GPCR Companies, 2024*
Table 20 : Sources Used in this Report
Table 21 : Abbreviations Used in this Report
Table 22 : Agilent Technologies Inc.: Company Snapshot
Table 23 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
Table 24 : Agilent Technologies Inc.: Product Portfolio
Table 25 : BD: Company Snapshot
Table 26 : BD: Financial Performance, FY 2023 and 2024
Table 27 : BD: Product Portfolio
Table 28 : Danaher Corp.: Company Snapshot
Table 29 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 30 : Danaher Corp.: Product Portfolio
Table 31 : Enzo Biochem Inc.: Company Snapshot
Table 32 : Enzo Biochem Inc.: Financial Performance, FY 2023 and 2024
Table 33 : Enzo Biochem Inc.: Product Portfolio
Table 34 : Epics Therapeutics: Company Snapshot
Table 35 : Epics Therapeutics: Product Portfolio
Table 36 : Eurofins Scientific: Company Snapshot
Table 37 : Eurofins Scientific: Financial Performance, FY 2022 and 2023
Table 38 : Eurofins Scientific: Product Portfolio
Table 39 : InterAx Biotech AG: Company Snapshot
Table 40 : InterAx Biotech AG: Product Portfolio
Table 41 : Merck KGaA: Company Snapshot
Table 42 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 43 : Merck KGaA: Product Portfolio
Table 44 : Orion Biotechnology Canada Ltd.: Company Snapshot
Table 45 : Orion Biotechnology Canada Ltd.: Product Portfolio
Table 46 : Promega Corp.: Company Snapshot
Table 47 : Promega Corp.: Product Portfolio
Table 48 : Promega Corp.: News/Key Developments, 2023 and 2024
Table 49 : Qiagen: Company Snapshot
Table 50 : Qiagen: Financial Performance, FY 2022 and 2023
Table 51 : Qiagen: Product Portfolio
Table 52 : Revvity: Company Snapshot
Table 53 : Revvity: Financial Performance, FY 2022 and 2023
Table 54 : Revvity: Product Portfolio
Table 55 : Revvity: News/Key Developments, 2021
Table 56 : Tectonic Therapeutic: Company Snapshot
Table 57 : Tectonic Therapeutic: Product Portfolio
Table 58 : Tectonic Therapeutic: News/Key Developments, 2024
Table 59 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 60 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 61 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 62 : Wuxi AppTec: Company Snapshot
Table 63 : Wuxi AppTec: Financial Performance, FY 2022 and 2023
Table 64 : Wuxi AppTec: Product Portfolio

List of Figures

Summary Figure : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
Figure 1 : Snapshot of the Market Dynamics for GPCR-Targeting Technologies
Figure 2 : Global Market Shares for GPCR-Targeting Technologies, by Assay Type, 2023
Figure 3 : Global Market Shares for GPCR-Targeting Technologies, by Product Type, 2023
Figure 4 : Global Market Shares for GPCR-Targeting Technologies, by Application, 2023
Figure 5 : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
Figure 6 : North American Market Shares for GPCR-Targeting Technologies, by Country, 2023
Figure 7 : European Market Shares for GPCR-Targeting Technologies, by Country, 2023
Figure 8 : APAC Market Shares for GPCR-Targeting Technologies, by Country, 2023
Figure 9 : ROW Market Shares for GPCR-Targeting Technologies, by Subregion, 2023
Figure 10 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 11 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
Figure 12 : BD: Revenue Share, by Business Unit, FY 2024
Figure 13 : BD: Revenue Share, by Country/Region, FY 2024
Figure 14 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
Figure 15 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 16 : Enzo Biochem Inc.: Revenue Share, by Country/Region, FY 2023
Figure 17 : Eurofins Scientific: Revenue Share, by Business Unit, FY 2023
Figure 18 : Eurofins Scientific: Revenue Share, by Country/Region, FY 2023
Figure 19 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 20 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 21 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 22 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 23 : Revvity: Revenue Share, by Business Unit, FY 2023
Figure 24 : Revvity: Revenue Share, by Country/Region, FY 2023
Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023
Figure 27 : Wuxi AppTec: Revenue Share, by Business Unit, 2023
Figure 28 : Wuxi AppTec: Revenue Share, by Country/Region, 2023